Long-term mortality after blood pressure-lowering and lipid-lowering treatment in patients with hypertension in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy study: 16-year follow-up results of a randomised factorial trial

Lancet
Ajay GuptaPeter S Sever

Abstract

In patients with hypertension, the long-term cardiovascular and all-cause mortality effects of different blood pressure-lowering regimens and lipid-lowering treatment are not well documented, particularly in clinical trial settings. The Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy Study reports mortality outcomes after 16 years of follow-up of the UK participants in the original ASCOT trial. ASCOT was a multicentre randomised trial with a 2 × 2 factorial design. UK-based patients with hypertension were followed up for all-cause and cardiovascular mortality for a median of 15·7 years (IQR 9·7-16·4 years). At baseline, all patients enrolled into the blood pressure-lowering arm (BPLA) of ASCOT were randomly assigned to receive either amlodipine-based or atenolol-based blood pressure-lowering treatment. Of these patients, those who had total cholesterol of 6·5 mmol/L or lower and no previous lipid-lowering treatment underwent further randomisation to receive either atorvastatin or placebo as part of the lipid-lowering arm (LLA) of ASCOT. The remaining patients formed the non-LLA group. A team of two physicians independently adjudicated all causes of death. Of 8580 UK-based patients in ASCOT, 3282 (38·3%) died, including...Continue Reading

Citations

Oct 9, 2018·Expert Review of Cardiovascular Therapy·Dhruv MahttaCarl J Pepine
Mar 31, 2019·British Journal of Pharmacology·Qin FangDao Wen Wang
Jul 18, 2019·Journal of Food Science·Rongrong LuZhuoqin Jiang
Jul 17, 2019·Journal of Cardiovascular Pharmacology·Song ZhangYue Li
Oct 15, 2019·Current Opinion in Lipidology·Chris J Packard
May 31, 2019·Journal of Hypertension·Costas Thomopoulos, Christina Antza
Feb 29, 2020·Journal of Cardiovascular Pharmacology and Therapeutics·John B KostisWilliam J Kostis
May 9, 2019·Advances in Therapy·Katie LindenIan B A Menown
Oct 4, 2020·Journal of the Chinese Medical Association : JCMA·Kang-Ling WangChern-En Chiang
Jan 8, 2021·Hormones : International Journal of Endocrinology and Metabolism·J A PapadakisG Vrentzos
Oct 28, 2020·Nutrients·Esther Viñas EsmelEmilio Sacanella Meseguer
Jul 2, 2021·Stroke; a Journal of Cerebral Circulation·William N WhiteleyPeter S Sever

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.